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(10.4% in the French Regist~), furthermore the prevention of restenosis by
stenting has not bean proven in small arteries. To assess the feasibility and
the safety of elective Stenting in small arterfes, we conducted a prospective
pilot study in two Institutions with 100 pts electively stented with a 2.5 mm
AVE microstent. Patients had stable or unstable angina, single or multivessel
disease, slngleormuitlple PTCAsites butat least one lesion inasmallve$sel.
End points were: in-hospital events and angiographic patency of the stented
arteries at 6 months. Fifty six pts (mean age 62.5 * 12.3) recaived 65 (1.1
stentdpts) 2.5 mm microstents. Reasons for stenting were: 68% elective,
10% SubOptimalreSUkS,19Y0 non- occlusive dissection and 3% restenosia.
QCA results: meananerydiameter was 2.34 (1.9-2.6) mm. The patients
were treated with 100 mg Aspirin and 250 to 500 mg of Ticlopidine for one
month.
Resu/ra:during hospital stay, no patient died, had surgery or an Ml. Fifteen
pts had their 6-month angiogram, no stent was occluded, 5 (30%) pts had
restenosis at the stent site and had repeat PTCA.
In conclusion: Coronary stenting of small aileries with 2.5 mm microatent
seems to be feasible and safe. This pilot study will be followed by a random-
ized trial which will comparethe restenosisrateof 2.5 mmmicrostentAvE
with GOBA.
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Immediate Stent Therapy for High Risk Saphenoua
Vein Graft Lesions
M.K. Hong, L.F. Satler, K.M. Kent, A.D. Pichard, J.J. Popma, G.S..Mintz,
T.A. Bucher, A. Greenberg, K. Morgan, T. Weaver, B. Golden, B. Keere,
M.K. Kehoe, M.B. Leon. Washington Hospital Cente~ Washington,DC, USA
Previously, we showad favorable pmeedural results of debulking [with ex-
cimer laser or transluminal extraction catheter (TEC)] prior to immediate
stenting for high risk saphenous vein graft lesions (total occlusions, intragrafl
thrombus, or graft degeneration). To determine the late outcome in these
patients, we performed ?6-month follow-uP of 131 cons~utive Patientswith
196 lesions (saphenous vein graft age= 102&42 months) treated using this
multi-device strategy.
Laser+ Stent (N = 146) TEC + Stent(N= 50)
Prcaeduralsuccess f%) 98.9 100
% Complication(DeitWM1/CABG) 0/0/1.1 0/0/0
Subacutethrombosis(“A) o 0
“ATLR (PTCA/CABG) 6.9 (2.7/4.1) 6 (2/4)
% EFS (death/Ml/revaeculariZatiOn) e7 (9/4/20) 73 (5/0/21)
TLR = Target lesionrevascularization;EFS = Event-free survival.
In wnchsion, the atrategy of debulking foliowad by immediate adjunct
stent therapy in high-risk saphenous vein graft iesions results in favorable
acute and 6-month TLR. However, despite the low TLR, these patients still
have reduced EFS due to high mortality (overall 8%) and frequent revascu-
Iarization involving rm-target lesion sitas.
D90448 Long-Term Follow-Up of a High Risk CohorlFollowing Stent Implantation in Saphenous Vein
Grafts
A. Frimerman, N. Eigler, M.R. Payton, F. Litvack. Cedars-Sinai Medical
Center, Loa Angeles, California, USA
To assesa the iong-term clinical outcome of high risk patients following J&J
stent implantation in vein graft (VG), we studied 177 patienta (156 males,
302 stente, 244 iesions) with a mean F/U of 19.6 *13 months (range 7-59).
Ninety percent originally presented with Ml or class IV angina; mean EF =44
l 11;age= 71 * 9 years; graft mean age= 9.4•5 years. Using a risk score
ciaaeification, 155 (67Yo)patients were defined as high risk for repeat surgery
or PTCA. The following clinical events were analyzed: Death (cardiac), Ml,
repeatCABG, repeat PTCA, angina level using the 1 to4 CCSF classification
and activity Ievei using the 1 to 4 Specific Activity Scale (SAS). Event-free
survival rates in the sequential years after stenting were eatimated using
Kapian-Meir (KM) method, and the Cox proportional hazard model was used
to anaiyze the predictive importance of 52 clinical and technical variables.
Resu/fa:The clinicai evant rates (hierarchical) were: Daath = 14 (6%), Ml
= 15 (6.5%), CABG = 20 (11%), PTCA = 25 (14%), Total = 74 (42%).
Table:KMestimateofsurvivalandevent free survival
t ‘fear 2 Years 3 Yeare 4 Years
YeSurvival 95*2 92& 3 S9*4 82 k 6
% Evant free 69*4 54 i 5 31 *6 22& 6
O.Ot).Mean CCSF= 1.1+ 1.1, mean SAS= 1.8~ 1.1.Totai revsacularization
\ proceduresware64 (36%)from which 14were in non target lesion. Fifty three
percent of the cardiac events occurred during the first year of F/U (36% in
first 6 months).
CorIc/IJsiIYns:High risk patients maintain reasonable survival and func-
tional state following stent placement in stenotic VG, but the iong.term event
free sutvival is poor mainiy due to the need for repeat revascularization
occurring mostiy in the first year after stenting but continuing significantly
beyond this period,
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FoffowingTranscatheter intervention: Six Month
Angiographlc Findings from the SAVED Trial
D.L. Fischman, S. Bailey, S. Goldberg, J.S. Douglas, Jr., S.H. Fenton,
P.Overlie, R. Rake, S. Gebhardt, C. Dempsey, M.P.Savage for the SAVED
investigators. Jefferson Medics/ Co//ege, /W/ade/p/ria, PA, USA
Previous reports have implied a lower thrombosis rate for stents piaced in
saphenous vein grafts compared to nativa coronary arteries. However, the
clinical presentation of stent thrombosis may be more subtle in patients
with prior CABG due to collateral circulation or presefved fiow In the native
vessel. As part of the SAVED trial, a randomized comparison of angioplaaty
(PTCA) to stent in saphenousveinbypassgrafts,we soughtto determine
the incidence of early and late vessei ciosure. 110 patients were randomized
to PTCA and 110 to stent with 6 month angiographic follow-up performed
in 87% of eligible patients. Clinical documentation of early stent thrombosis
(0-30 daya) was reported in cnly one patient (l%). On the other hand, late
angiographic foliow-up (mean 6.3 months), revealed target vessel occlusion
in 9/95 (9%) of stent patients and in 5/67 (6%) of PTCA patienta (p = ns).
However, only 3 of 9 (33%) stented patients with compiete graft occlusion
demonstrated by late angiography had a major cardiac event (death or
Ml). In conclusion, vein graft occlusion within 6 months occurs frequently
foilowing transcatheter intervention and may be inherent to the biology of
this circulation. Because total occlusion of bypass grafts following coronary
intervention are infrequently accompanied by major clinical events, the true
incidence of stent thrombosis in saphenous vein bypass grafts may have
bean underestimated by previous studies.
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From Triaf of Angiopfaaty and Stenta in Canada
(TASC 1)
A. Chauhan, D.R. Ricci, C.E. Buller, L. Roy, C. Lazzam, G. Barbeau,
R. Brown, D. Almond, J.-F. Marquis, B.J. O’Neiil, D.L. Fischman, J.G. Webb,
B. Foley, L. Rizo, K. Sridhar, C. Wong, I.M. Penn. Vancouver Hospital,
Vancouvefi BC, Canada
TASC I was a mulficentre trans-Canada study that randomized 270 patients
to receive either conventional PTCA or a Palmaz-Schatz coronary stent in
the setting of elactive angiopiasty during April 1991 to January 1994. This
provides us with the oppoflunity to compare the effect of stents versus PTCA
on clinicai outcome (procedure to end of study) in tha LAD veraua non-LAD
subgroups to determine any difference which may be important in clinical
decision making. The maan follow-up was 6.6* 2.6 months.
LAD Non-LAD
Stent PICA Stent PTCA
Number 61 57 76 76
Death o 2 (3.5) 1 (1.3) o
Mi 3 (4.9) 1 (t .6) 7 (9.2) 1 (1.3)*
CABG 2 (3.3) 5 (8.8) 4 (5,3) t (1,3)
Rpt PTCA 3 (4.9) 6 (10.5) 11 (14,5) 6 (10.5)
Any Event 6 (9.8) 12 (21.1)* 13 (17.1) 10 (13.2)
Any Event incl.bailout 6 (9.8) 20 (35.1)’* 13 (17.1) 13 (17.1)
* P = 0.09; *“ P = 0.0009
A strategy of stenting as compared to PTCA in the LAD subgroup was
associated with a lower event rate. Stenting in the non-LAD territories con-
ferred nonclinicalbenefit over PTCA. This has implications on the current use
and “over-use” of stents.
Predictors of death were CHF (p < 0.01) and LVEF < 45% (p < 0.05).
Predictors of totai events were LVEF < 45% (p < 0.01) and high VG age (p <
